Ichthyosis is a medical condition that causes widespread and persistent thick, dry, "fish-scale" skin. It is a group of skin disorders that lead to dry and itchy skin that appears scaly, rough, and red. The symptoms can range from mild to severe. Ichthyosis can affect only the skin, but some forms of the disease can affect internal organs as well. There are more than 20 different types of ichthyosis. Some types are inherited at birth, and others are acquired during adulthood. The treatment helps reduce the redness of the skin, thickness of the scales, and itching.

Market Dynamics:

The rise in burden of fish skin disease, the rise in awareness among people, the increase in demand for safe, effective treatments & therapies, and the introduction of novel treatments and therapies by market players are major factors expected to propel growth of the global fish skin disease market.

For instance, in April 2023, Kerecis, a manufacturer of fish skin-based therapeutic products announced the launch of the MariGen Shield, a solution that combines the company’s fish-skin graft and a silicone contact layer to treat chronic and complex wounds. The silicone contact layer anchors the round graft in position and help safeguard granulating wound

Moreover, in October 2021, Kerecis received the U.S. Food and Drug Administration (FDA) marketing authorization for Omega3 SurgiBind. It is an implantable fish-skin graft intended for use in plastic and reconstructive surgery. It is indicated for strengthening weak soft tissue in patients who require soft tissue repair or reinforcement in plastic or reconstructive surgery.

Key features of the study:

• This report provides in-depth analysis of the global fish skin disease market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–20230), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fish skin disease market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include GSK Plc., AbbVie Inc., Sonnet BioTherapeutics, Krystal Biotech, LEO Pharma, GALDERMA, GLENMARK PHARMACEUTICALS LTD., Mayne Pharma Group Limited, Ortho Dermatologics, Cellegy Pharmaceuticals, Patagonia Pharmaceuticals, LLC, Crown Laboratories, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global fish skin disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fish skin disease market

Fish Skin Disease Market Detailed Segmentation:

• By Type:
  • Ichthyosis vulgaris
  • X-linked recessive ichthyosis
  • Others (Autosomal recessive congenital ichthyosis, etc.)
• By Treatment Type:
  • Corticosteroids
  • Emollients
  • Retinoids
  • Others (Keratolytics, etc.)
• By Route of Administration:
  • Topical
  • Oral
  • Parenteral
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles:
  • GSK Plc.
  • AbbVie Inc.
  • Sonnet BioTherapeutics
  • Krystal Biotech
  • LEO Pharma
  • GALDERMA
  • GLENMARK PHARMACEUTICALS LTD.
  • Mayne Pharma Group Limited
  • Ortho Dermatologics
  • Cellegy Pharmaceuticals
  • Patagonia Pharmaceuticals, LLC
  • Crown Laboratories, Inc.